This animated video highlights the key efficacy and safety data from the COMBI-AD Phase III clinical trial assessing TAFINLAR (dabrafenib) and MEKINIST (trametinib) for the adjuvant treatment of adult patients with BRAF V600-positive Stage III melanoma, following complete resection1.
Further data from the COMBI-AD trial can be viewed here.
References
- Hauschild A, et al. J Clin Oncol 2020; 38(suppl) [abstract 10001].
- The Cancer Genome Atlas Network. Cell 2015; 161(7):1681-1696.
- Hayward NK, et al. Nature 2017; 545(7653):175-180.
- Rabbie R, et al. J Pathol 2019; 247(5):539-551.
- Ives NJ, et al. Eur J Cancer 2017; 82:171-183.
- Michielin O, et al. Ann Oncol 2019; 30(12):1884-1901.
- Hauschild A, et al. J Clin Oncol 2018; 36(35):3441-3449.
- Long GV, et al. N Engl J Med 2017; 377(19):1813-1823.
- Eggermont AM, et al. J Clin Oncol 2020; 38(suppl) [abstract 10000].
- Schadendorf D, et al. Lancet Oncol 2019; 20(5):701-710.
- Atkinson V, et al. Presented at ESMO 2018; 19-23 October, Munich, Germany.
- Long GV, et al. Presented at SMR 2017; 18-21 October, Brisbane, Australia.
- Novartis Pharmaceutical Corp. Data on file 2018.
- TAFINLAR (dabrafenib) Summary of Product Characteristics.
- MEKINIST (trametinib) Summary of Product Characteristics.
- OPDIVO (nivolumab) Summary of Product Characteristics.
- KEYTRUDA (pembrolizumab) Summary of Product Characteristics.
- Eek D, et al. Patient Prefer Adherence 2016; 10:1609-1621.
Rate this content:
UK | December 2020 | 100924
